ANNX VS INGN Stock Comparison

Performance

ANNX
10/100

ANNX returned -58.14% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

INGN
10/100

INGN returned -75.55% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

ANNX
72/100

ANNX had a bullish sentiment score of 71.85% across Twitter and StockTwits over the last 12 months. It had an average of 2.00 posts, 0.00 comments, and 0.07 likes per day.

INGN
78/100

INGN had a bullish sentiment score of 78.42% across Twitter and StockTwits over the last 12 months. It had an average of 3.50 posts, 0.00 comments, and 0.00 likes per day.

Technicals

ANNX
64/100

ANNX receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

INGN
64/100

INGN receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

ANNX
10/100

ANNX has missed earnings 7 times in the last 20 quarters.

INGN
23/100

INGN has missed earnings 5 times in the last 20 quarters.

Profit

ANNX
10/100

Out of the last 19 quarters, ANNX has had 0 profitable quarters and has increased their profits year over year on 1 of them.

INGN
24/100

Out of the last 20 quarters, INGN has had 7 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

ANNX
49/100

ANNX has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

INGN
41/100

INGN has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.

Analyst Price Targets

ANNX

"Analyst Price Targets" not found for ANNX

INGN
79/100

6 analysts offer 12-month price targets for INGN. Together, they have an average target of 26, the most optimistic target put INGN at 26 within 12-months and the most pessimistic has INGN at 26.

All score calculations are broken down here to help you make more informed investing decisions

Annexon, Inc. Common Stock Summary

Nasdaq / ANNX

Healthcare

Biotechnology

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Inogen Inc Summary

Nasdaq / INGN

Healthcare

Medical - Devices

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Power up your portfolio